Search
Citas y referencias (13)
Gibco™
StemPro™ MSC SFM XenoFree
El medio de cultivo sin suero (SFM) para células madre mesenquimales (MSC) GIBCO® StemPro® se ha diseñado para el crecimientoMás información
| Número de catálogo | Cantidad |
|---|---|
| A1067501 | 1 Kit |
Número de catálogo A1067501
Precio (CLP)
643.745
Each
Cantidad:
1 Kit
Precio (CLP)
643.745
Each
El medio de cultivo sin suero (SFM) para células madre mesenquimales (MSC) GIBCO® StemPro® se ha diseñado para el crecimiento y la expansión de células madre mesenquimales humanas (MSC) y células madre derivadas de tejido adiposo (ADSC) en condiciones totalmente exentas de suero y xenógenos. Con el SFM para MSC StemPro® XenoFree, las MSC o ADSC humanas se pueden expandir en varios pasajes a la vez que mantienen su fenotipo multipotente (es decir, la capacidad para diferenciarse en los linajes osteogénicos, condrogénicos y adipogénicos). El SFM para MSC StemPro® XenoFree cumple con las buenas prácticas de fabricación actuales, lo que posibilita la trazabilidad y permite una fabricación fiable.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Tipo de célulaCélulas madre mesenquimales
Entorno de cultivoCO2
Antibióticos incluidosSin antibióticos
Línea de productosStemPro
Tipo de productoMedio libre de suero (SFM) de células madre
Grado de pureza o calidadCélulas madre embrionarias (MS) cualificadas
Cantidad1 Kit
EspecieHumano
ClasificaciónSin componentes xenobióticos
Culture TypeCultivo celular adherente
FormularioLíquido
Serum LevelSin suero
Sin aditivosSin glutamina, Sin rojo fenol
Unit SizeEach
Contenido y almacenamiento
Cada kit contiene 1 x 500 ml medio basal SFM para MSC StemPro™ y 1 x 5 ml suplemento SFM para MSC sin xenógenos StemPro™. El medio basal SFM para MSC StemPro™ se almacena entre 2 y 8 °C y es estable durante 12 meses. El suplemento sin xenógenos SFM para MSC StemPro™ se almacena entre -5 y -20 °C y es estable durante 12 meses.
Preguntas frecuentes
What is the concentration of sodium bicarbonate in StemPro MSC SFM XenoFree?
Citations & References (13)
Citations & References
Abstract
Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity.
Journal:Molecular therapy : the journal of the American Society of Gene Therapy
PubMed ID:30341012
Exosomes can deliver therapeutic RNAs to neurons. The composition and the safety profile of exosomes depend on the type of the exosome-producing cell. Mesenchymal stem cells are considered to be an attractive cell type for therapeutic exosome production. However, scalable methods to isolate and manufacture exosomes from mesenchymal stem cells
Diverse impact of xeno-free conditions on biological and regenerative properties of hUC-MSCs and their extracellular vesicles.
Journal:Journal of molecular medicine (Berlin, Germany)
PubMed ID:27638341
ABSTRACT: Growing evidence indicates that intracellular signaling mediated by extracellular vesicles (EVs) released by stem cells plays a considerable role in triggering the regenerative program upon transplantation. EVs from umbilical cord mesenchymal stem cells (UC-MSC-EVs) have been shown to enhance tissue repair in animal models. However, translating such results into
Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions.
Journal:Tissue engineering. Part C, Methods
PubMed ID:21895491
The immunomodulatory properties of mesenchymal stem cells (MSCs) make them attractive therapeutic agents for a wide range of diseases. However, the highly demanding cell doses used in MSC clinical trials (up to millions of cells/kg patient) currently require labor intensive methods and incur high reagent costs. Moreover, the use of
A xeno-free microcarrier-based stirred culture system for the scalable expansion of human mesenchymal stem/stromal cells isolated from bone marrow and adipose tissue.
Journal:
PubMed ID:26136376
'Human mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and the development of microcarrier-based cultures in scalable bioreactors with well-defined xenogeneic-free components represent important milestones towards the clinical-scale production of these cells. In this work, we optimized our previously developed xeno-free microcarrier-based system for the scalable expansion of
Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media.
Journal:
PubMed ID:26564250
'Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been evaluated for the treatment of immunological diseases. However, the animal-derived growth supplements utilized for MSC manufacturing may lead to clinical complications. Characterization of alternative media formulations is imperative for MSC therapeutic application. Human BMMSC and AdMSC were expanded in